Abstract：Objective: To investigate the value of 18F-FDG PET/CT imaging in the diagnosis of retroperitoneal fibrosis. Materials and Methods: A retrospective analysis of 18 cases with retroperitoneal fibrosis from January 2013 to October 2016 confirmed by imaging examination with clinical follow-up of more than one year(10 cases) and pathology(8 cases) was performed, including 7 cases in the active phase and 11 cases in the inactive phase with evidence from serum laboratory findings(obviously hige C reactive protein and erythrocyte sedimentation rate). Results: The CT images of 18 patients showed irregular soft tissue masses in retroperitoneum, with unclear boundaries often involving the abdominal aorta, iliac artery, ureter and so on. Five of the 7 patients in the active phase were initially diagnosed, with increased FDG uptake in the masses on PET images. The rest 2 patients had already begun their steroid treatment since 2 and 2.5 months ago respectively, with no significant increase in FDG metabolism on PET images. In the 11 patients with inactive retroperitoneal masses which were initially diagnosed, the FDG metabolism varied. Conclusion: 18F-FDG PET/CT can clearly show the range of retroperitoneal fibrosis by CT, and FDG metabolism on PET is helpful to determine whether the lesion is in the active phase and to evaluate the effect of steroid treatment.
张立欧，孙洪赞，卢再鸣. 18F-FDG PET/CT在诊断腹膜后纤维化中的价值#br#[J]. 中国临床医学影像杂志, 2017, 28(4): 264-267.
ZHANG Li-ou, SUN Hong-zan, LU Zai-ming. The value of 18F-FDG PET/CT in the diagnosis of retroperitoneal fibrosis. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(4): 264-267.
[1]Greco P, Vaglio A, Manenti L, et al. Idiopathic retroperitoneal fibrosis[J]. G Ital Nefrol, 2004, 21(2): 132-138.
[2]李清勇. 64排螺旋CT在诊断腹膜后纤维化中的应用价值[J]. 医药论坛杂志，2013，34（4）：134-135.
[3]Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis[J]. Lancet, 2006, 367(9506): 241-251.
[4]余成秀，罗雄燕，邹倩，等. LgG4与自身免疫病[J]. 中华风湿学杂志，2012，16（12）：838-840.
[5]陈永刚，戴岷. 隐匿起病的腹膜后纤维化3例临床分析[J]. 中国医师杂志，2015（s1）：158-159.
[6]Fofi C, Prosperi D, Pettorini L, et al. Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of 18F-FDG-PET/CT and biochemical parameters in patients with renal involvement[J]. Intern Emerg Med, 2016, 11(6): 809-816.
[7]Washino S, Hirai M, Matsuzaki A, et al. 18F-Fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis[J]. Ann Nucl Med, 2010, 24(3): 225-229.
[8]Nakajo M, Jinnouchi S, Tanabe H, et al. 18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis[J]. J Comput Assist Tomogr, 2007, 31(4): 539-543.
[9]Moroni G, Castellani M, Balzani A, et al. The value of 18F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis[J]. Eur J Nucl Med Mol Imaging, 2012, 39(10): 1635-1642.
[10]Jansen I, Hendriksz TR, Han SH, et al. 18F-fluorodeoxyglucose position emission tomography(FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis[J]. Eur J Intern Med, 2010, 21(3): 216-221.
[11]张警丰，赵金霞，刘湘源. 特发性腹膜后纤维化诊治研究进展[J]. 中华风湿病学杂志，2015，19（8）：567-569.
[12]Treglia G, Mattoli MV, Bertagna F, et al. Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review[J]. Rheumatol Int, 2013, 33(3): 549-555.
[13]Bertagna F, Treglia G, Leccisotti L, et al. [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience[J]. Jpn J Radiol, 2012, 30(5): 415-421.
